Mironid doses initial cohorts in Phase 1 ADPKD drug trial
AI Summary- Mironid dosed initial cohorts in its Phase 1 trial of a LoAc® small molecule for ADPKD.
- 48 healthy volunteers may be enrolled across six sequential single-ascending-dose cohorts.
- The dosing followed Clinical Trial Application approval and moved Mironid into clinical-stage development.